Injectable Anabolic Biomaterials for Bone Regeneration
Injectable Anabolic Biomaterials for Bone Regeneration
批准号:
8654258
负责人:
Lakshmi S Nair
金额:
$14.09万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2017-04-30
关键词:
AKT Signaling PathwayAddressAdoptedAlkaline PhosphataseAnimal ModelApoptosisApoptoticBiocompatible MaterialsBiologicalBiomechanicsBone MarrowBone Marrow TransplantationBone RegenerationCalciumCalvariaCell Culture TechniquesCell DeathCell Differentiation processCell ProliferationCell SurvivalCell TherapyCell TransplantationCell TransplantsCell physiologyCellsCharacteristicsClinicalClinical TrialsComplexDefectDepositionDevelopmentDiseaseEncapsulatedEngineeringEvaluationFaceFamilyGelGelatinGlycoproteinsGoalsHealedHistological TechniquesHumanImaging TechniquesIn VitroInflammatoryInjectableInjuryIronIron-Binding ProteinsLaboratoriesLactoferrinLightMesenchymal Stem Cell TransplantationMesenchymal Stem CellsModelingMusculoskeletalNatural regenerationOrganOsteoblastsOsteocalcinOsteogenesisPerformancePhenotypePilot ProjectsPropertyRattusRecombinantsResearchSerumSiteSourceStagingStem cellsTechnologyTestingTherapeuticTissue EngineeringTissuesTransferrinTranslationsTransplantationVascularizationbasebody systembonedesignhealingimprovedin vivoin vivo Modelinjuredinsightmemberosteoblast differentiationosteogenicosteogenic proteinosteopontinpreventregenerativerepositoryresponseself-renewalskeletalskeletal regenerationstemsuccesstissue regenerationwound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): PROJECT SUMMARY Cell transplantation is emerging as a promising clinical strategy to accelerate tissue regeneration. However, the successful clinical translation of this technology faces several engineering and biological challenges. Major challenges lies in our inability to deliver and retain the transplanted cells at the healing site and prevent the uncontrolled cell death in the unfriendly milieu of the injured tissue. The long-range goal of our laboratory is to regenerate complex tissues, organs and organ systems using the principles of regenerative engineering with advanced biomaterials and unique cell sources. One of our immediate objectives is to design cell delivery vehicles that will transiently act as a favorable microenvironment at the healing site to modulate cell performance upon transplantation. The aim of the proposed study is to evaluate the efficacy of an injectable biomaterial based on lactoferrin as an artificial microenvironment to increase the survival and osteogenic activity of encapsulated rat mesenchymal stem cells (rBMSC). The proposed research is designed based on our preliminary studies demonstrating the anti-apoptotic, mitogenic and osteogenic effect of soluble recombinant human lactoferrin (rhLf). The hypothesis being tested is that the injectable recombinant human lactoferrin gel (rhLfG) will present a favorable osteostimulative microenvironment by inhibiting cellular apoptosis and promoting cell proliferation and osteogenic differentiation. The experimental plan will explore the bioactivity of
the injectable recombinant human lactoferrin gel based cell delivery vehicle through two specific aims. The first aim is designed to evaluate in vitro the anti apoptotic, mitogenic and osteogenic effect of recombinant human lactoferrin gels (rhLfG) to rat bone marrow derived mesenchymal stem cells. Cell culture conditions that are known to induce cellular apoptosis will be used. An injectable gelatin gel will be used as a control matrix to evaluate the efficacy of lactoferrin gel
microenvironment in improving cell survival and promoting cell proliferation and differentiation. The second aim is designed to evaluate in vivo the efficacy of the injectable rhLfG in enhancing rBMSC survival, proliferation and osteogenesis, using a rat calvarial bone defect model. We hypothesize that the biologically active microenvironment provided by rhLfG will promote bone regeneration and better host tissue integration upon rBMSC delivery compared to injectable gelatin delivery vehicle. The proposed pilot study will help to understand the feasibility of developing a cell instructive injectable regenerative biomaterial based on rhLf as a cell delivery vehicle for bone regeneration. If successful, the injectable lactoferrin based delivery vehicle could have a significant impact in the clinical translation of cell based therapeutic strategies by
addressing some of its current limitations.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.ijbiomac.2012.12.045
发表时间:
2013-04
期刊:
International journal of biological macromolecules
影响因子:
8.2
作者:
[Ganesh N, Hanna C, Nair SV, Nair LS]
通讯作者:
Nair LS
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10655730
-
项目类别:
-
资助金额:$7.14万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10657572
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10440368
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10428994
-
项目类别:
-
资助金额:$7.14万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10852320
-
项目类别:
-
资助金额:$7.14万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:9977127
-
项目类别:
-
资助金额:$43.17万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Novel injectable analgesic delivery system for musculoskeletal pain management
-
批准号:10179323
-
项目类别:
-
资助金额:$34.95万
-
财政年份:2019
-
负责人:Lakshmi S Nair
-
依托单位:
Injectable Anabolic Biomaterials for Bone Regeneration
-
批准号:8682752
-
项目类别:
-
资助金额:$5.71万
-
财政年份:2012
-
负责人:Lakshmi S Nair
-
依托单位:
Injectable Anabolic Biomaterials for Bone Regeneration
-
批准号:8366964
-
项目类别:
-
资助金额:$7.52万
-
财政年份:2012
-
负责人:Lakshmi S Nair
-
依托单位:
Injectable Anabolic Biomaterials for Bone Regeneration
-
批准号:8487370
-
项目类别:
-
资助金额:$7.14万
-
财政年份:2012
-
负责人:Lakshmi S Nair
-
依托单位:
海外基金